Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F23%3A10457494" target="_blank" >RIV/00669806:_____/23:10457494 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10457494 RIV/00216208:11140/23:10457494 RIV/00064165:_____/23:10457494
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=8VHfjV_MpQ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=8VHfjV_MpQ</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s12325-023-02468-3" target="_blank" >10.1007/s12325-023-02468-3</a>
Alternative languages
Result language
angličtina
Original language name
Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe
Original language description
Fifty patients (Croatia: 25; Czech Republic: 20; Slovenia: 5) were enrolled. In patients continuing apremilast at 6 (+- 1) months, mean (+- SD) PASI score was reduced from 16.2 +- 8.7 points at treatment initiation to 3.1 +- 5.2 at 6 (+- 1) months; BSA from 11.9% +- 10.3% to 0.8% +- 0.9%; DLQI from 13.7 +- 7.4 points to 1.6 +- 3.2. PASI 75 was reached by 81% of patients. Physicians reported that the overall treatment success fulfilled their expectations in more than two thirds of patients (68%). At least three-quarters of patients reported apremilast had a quite or very high benefit on the needs they identified as being most important. Apremilast was well tolerated; no serious or fatal adverse events were identified.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Advances in Therapy
ISSN
0741-238X
e-ISSN
1865-8652
Volume of the periodical
40
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
16
Pages from-to
1787-1802
UT code for WoS article
000942688800001
EID of the result in the Scopus database
2-s2.0-85149232651